Obese Patients With Type 2 Diabetes (RIO-Diabetes)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00029848 |
Recruitment Status :
Completed
First Posted : January 24, 2002
Last Update Posted : April 20, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity Diabetes Mellitus, Non-Insulin-Dependent Obesity in Diabetes | Drug: Rimonabant (SR141716) | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1045 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes |
Study Start Date : | October 2001 |
Actual Primary Completion Date : | May 2004 |
Actual Study Completion Date : | May 2004 |

- Change in body weight
- Metabolic parameters

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- BMI must be greater than 27 and less than 40
- Treated Type 2 Diabetes on single therapy treatment for at least 1 year
- Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00029848

Study Director: | ICD CSD | Sanofi |
Responsible Party: | ICD Study Director, sanofi-aventis |
ClinicalTrials.gov Identifier: | NCT00029848 |
Other Study ID Numbers: |
EFC4736 |
First Posted: | January 24, 2002 Key Record Dates |
Last Update Posted: | April 20, 2009 |
Last Verified: | April 2009 |
Diabetes Obesity |
Diabetes Mellitus Obesity Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Overnutrition Nutrition Disorders Overweight Body Weight |
Rimonabant Anti-Obesity Agents Cannabinoid Receptor Antagonists Cannabinoid Receptor Modulators Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |